A survey conducted by TD Cowen indicates that artificial intelligence (AI) is significantly reducing costs and timelines in drug development, with some preclinical processes being expedited by as much as 70%. The survey involved 80 leaders in the biopharma sector and suggests that this acceleration is driving demand for advanced software, sequencing tools, and computer models to produce more experimental treatments over the next five years.
Brendan Smith, director of life sciences equity research at TD Cowen, noted that while AI cannot replace scientific intuition, it plays a crucial role in streamlining research and development prior to human testing. The survey also highlights a potential increase of over 10% in new drug development programs within three to five years, which could lead to an additional $1 billion in spending on technology and laboratory resources.
Despite these advancements, AI has yet to discover a drug that has received approval from the Food and Drug Administration (FDA). Some investors express skepticism regarding AI's potential impact on patient outcomes, citing concerns that current methodologies may not adequately account for human variability, which could maintain the high failure rate of new drugs at around 90%. Additionally, the competitive landscape is evolving, with China's biotech sector posing challenges to U.S. research efforts due to lower labor costs and faster turnaround times.